Pliant Therapeutics (PLRX) Other Non Operating Income (2019 - 2020)
Pliant Therapeutics (PLRX) posted quarterly Other Non Operating Income of -$97000.0 for Q4 2020, up 42.26% year-over-year from -$68184.1 in Q1 2020, and down 276.36% quarter-over-quarter from $55000.0 in Q3 2020.
Pliant Therapeutics (PLRX) Other Non Operating Income (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Other Non Operating Income for 2 consecutive years, with -$97000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Other Non Operating Income rose 42.26% year-over-year to -$97000.0; the TTM figure through Dec 2020 stood at -$346000.0 (changed N/A YoY), while the FY2025 annual figure was -$1.8 million, changed N/A from the prior year.
- Other Non Operating Income eased to -$97000.0 in Q4 2020 per PLRX's latest filing, from $55000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $55000.0 in Q3 2020 and bottomed at -$168000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -97,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | -136,000.00 |
| Dec 31, 2019 | -168,000.00 |
| Sep 30, 2019 | -41,000.00 |
| Jun 30, 2019 | -21,000.00 |